Boehringer In­gel­heim en­lists an­oth­er vir­tu­al biotech part­ner for its for­ay in­to reti­nal dis­eases

Boehringer In­gel­heim is bet­ting on reti­nal ther­a­pies in its lat­est deal and, in do­ing so, shin­ing the spot­light on a lit­tle-known biotech that has some new ideas about the kinds of dis­eases one can treat by tamp­ing down in­flam­ma­somes.

In­flam­ma­some Ther­a­peu­tics’ key con­tri­bu­tion to the co-de­vel­op­ment and li­cens­ing pact — which its big Ger­man part­ner is re­serv­ing $160 mil­lion for — is a tech­nol­o­gy that de­liv­ers drugs through in­ject­ing a long-act­ing, biodegrad­able gel for­mu­la­tion in­to the eye. The com­pounds will come from Boehringer’s grow­ing reti­nal dis­ease pipeline port­fo­lio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER